AR077764A1 - Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos - Google Patents

Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos

Info

Publication number
AR077764A1
AR077764A1 ARP100102628A ARP100102628A AR077764A1 AR 077764 A1 AR077764 A1 AR 077764A1 AR P100102628 A ARP100102628 A AR P100102628A AR P100102628 A ARP100102628 A AR P100102628A AR 077764 A1 AR077764 A1 AR 077764A1
Authority
AR
Argentina
Prior art keywords
hsa
conjugated
alfavbeta
integrine
variante
Prior art date
Application number
ARP100102628A
Other languages
English (en)
Spanish (es)
Original Assignee
Univ Nat Cheng Kung
Univ Nat Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Cheng Kung, Univ Nat Taiwan filed Critical Univ Nat Cheng Kung
Publication of AR077764A1 publication Critical patent/AR077764A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP100102628A 2009-07-20 2010-07-19 Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos AR077764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22694509P 2009-07-20 2009-07-20

Publications (1)

Publication Number Publication Date
AR077764A1 true AR077764A1 (es) 2011-09-21

Family

ID=43465728

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102628A AR077764A1 (es) 2009-07-20 2010-07-19 Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos

Country Status (14)

Country Link
US (1) US20110015130A1 (enExample)
EP (1) EP2456454A4 (enExample)
JP (1) JP2012533631A (enExample)
KR (1) KR20120097481A (enExample)
CN (1) CN102470156A (enExample)
AR (1) AR077764A1 (enExample)
AU (1) AU2010276453A1 (enExample)
CA (1) CA2768360A1 (enExample)
IL (1) IL217424A0 (enExample)
MX (1) MX2012000895A (enExample)
NZ (1) NZ597580A (enExample)
RU (1) RU2547592C2 (enExample)
TW (1) TWI557224B (enExample)
WO (1) WO2011011315A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US8357652B2 (en) * 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
KR20120130752A (ko) * 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
MX353816B (es) 2011-05-05 2018-01-30 Albumedix As Variantes de albumina.
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
EP3182988A4 (en) * 2014-08-22 2018-05-23 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
CN108430489B (zh) * 2015-06-28 2022-03-25 新源生物科技股份有限公司 用于抑制血管新生的融合蛋白
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
AU2019368816B2 (en) 2018-10-22 2025-01-30 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
CN114845710A (zh) 2019-11-27 2022-08-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN117321208A (zh) * 2021-03-16 2023-12-29 Km生物医药股份公司 经修饰的人血清白蛋白-硫氧还蛋白融合体
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
WO2026022392A1 (en) * 2024-07-26 2026-01-29 Ospedale San Raffaele S.R.L. Peptide and conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1990015072A1 (en) * 1989-06-07 1990-12-13 Genentech, Inc. Platelet aggregation inhibitors and related molecules
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
AU2002339862A1 (en) * 2001-09-04 2003-05-26 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
CA2465891C (en) * 2001-11-05 2012-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP1534718A4 (en) * 2002-06-07 2006-06-07 Wisconsin Alumni Res Found CHEMICAL SYNTHESIS OF REAGENTS FOR PEPTIDE COUPLING
WO2005090400A1 (en) * 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
WO2008056961A1 (en) * 2006-11-10 2008-05-15 Boryung Pharmaceutical Co., Ltd A novel fusion protein, cell lines expressing the same and preparation method thereof
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
KR20120130752A (ko) * 2009-12-23 2012-12-03 내셔널 타이완 유니버시티 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법

Also Published As

Publication number Publication date
NZ597580A (en) 2013-11-29
JP2012533631A (ja) 2012-12-27
US20110015130A1 (en) 2011-01-20
MX2012000895A (es) 2012-06-01
IL217424A0 (en) 2012-02-29
AU2010276453A1 (en) 2012-02-09
WO2011011315A1 (en) 2011-01-27
EP2456454A1 (en) 2012-05-30
CN102470156A (zh) 2012-05-23
TWI557224B (zh) 2016-11-11
KR20120097481A (ko) 2012-09-04
CA2768360A1 (en) 2011-01-27
EP2456454A4 (en) 2013-03-20
TW201107471A (en) 2011-03-01
RU2012105915A (ru) 2013-08-27
RU2547592C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
UY30166A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
UY32764A (es) Preparaciones insulinicas que comprenden metionina
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CL2008000121A1 (es) Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
UY30163A1 (es) Nuevas ariltienopirimidinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CR10900A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso los mismos
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
UY31922A (es) Compuestos
CL2015001615A1 (es) Una composicion farmaceutica que comprende vortioxetina y donepezilo junto con un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de disfuncion cognitiva, demencia en la enfermedad de alzheimer, disfuncion cognitiva asociada a la depresion y a la esquizofrenia, entre otras enfermedades.
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.

Legal Events

Date Code Title Description
FB Suspension of granting procedure